Isolina Rossi1, Philip Omotosho2, Jennifer Poirier2, Anna Spagnoli3, Alfonso Torquati4. 1. Department of Surgery, Carolinas Medical Center, Charlotte, NC. 2. Department of Surgery, Rush University Medical Center, Chicago, IL. 3. Department of Orthopedic Surgery, Rush University Medical Center, Chicago, IL. 4. Department of Surgery, Rush University Medical Center, Chicago, IL. Electronic address: Alfonso_Torquati@rush.edu.
Abstract
BACKGROUND: Obesity and type 2 diabetes mellitus are associated with elevated levels of inflammatory markers. This chronic inflammation is known to contribute to increased risk of cardiovascular disease in these populations. Laparoscopic Roux-en-Y gastric bypass is associated with a high rate of diabetes remission. We hypothesize that laparoscopic Roux-en-Y gastric bypass decreases systemic inflammatory markers and cardiovascular disease risk factors in obese diabetics. METHODS: This was a single-institution prospective cohort study of 61 obese patients with type 2 diabetes mellitus. A total of 30 patients underwent laparoscopic Roux-en-Y gastric bypass surgery, and 31 patients underwent standard medical therapy with diabetes support and education. Collected data included preoperative and postoperative inflammatory biomarkers and clinical parameters. RESULTS: Twelve months after undergoing laparoscopic Roux-en-Y gastric bypass, controlling for sex and age, there was a significant correlation between a change in interleukin-6 and a change in systolic blood pressure (Spearman r = 0.41, P = .03). Similarly, when sex and age were controlled for in the laparoscopic Roux-en-Y gastric bypass group, a statistically significant relationship remained between percent excess weight loss and change in interleukin-6 (P = .001). CONCLUSION: A significant relationship exists between decreased systemic interleukin-6 levels and both excess weight loss and lowered systolic blood pressure after laparoscopic Roux-en-Y gastric bypass in obese patients with diabetes mellitus. These correlations may explain the decreased risk of cardiovascular disease after surgical weight reduction in this patient population.
BACKGROUND: Obesity and type 2 diabetes mellitus are associated with elevated levels of inflammatory markers. This chronic inflammation is known to contribute to increased risk of cardiovascular disease in these populations. Laparoscopic Roux-en-Y gastric bypass is associated with a high rate of diabetes remission. We hypothesize that laparoscopic Roux-en-Y gastric bypass decreases systemic inflammatory markers and cardiovascular disease risk factors in obese diabetics. METHODS: This was a single-institution prospective cohort study of 61 obese patients with type 2 diabetes mellitus. A total of 30 patients underwent laparoscopic Roux-en-Y gastric bypass surgery, and 31 patients underwent standard medical therapy with diabetes support and education. Collected data included preoperative and postoperative inflammatory biomarkers and clinical parameters. RESULTS: Twelve months after undergoing laparoscopic Roux-en-Y gastric bypass, controlling for sex and age, there was a significant correlation between a change in interleukin-6 and a change in systolic blood pressure (Spearman r = 0.41, P = .03). Similarly, when sex and age were controlled for in the laparoscopic Roux-en-Y gastric bypass group, a statistically significant relationship remained between percent excess weight loss and change in interleukin-6 (P = .001). CONCLUSION: A significant relationship exists between decreased systemic interleukin-6 levels and both excess weight loss and lowered systolic blood pressure after laparoscopic Roux-en-Y gastric bypass in obese patients with diabetes mellitus. These correlations may explain the decreased risk of cardiovascular disease after surgical weight reduction in this patient population.
Authors: Philip R Schauer; Deepak L Bhatt; John P Kirwan; Kathy Wolski; Ali Aminian; Stacy A Brethauer; Sankar D Navaneethan; Rishi P Singh; Claire E Pothier; Steven E Nissen; Sangeeta R Kashyap Journal: N Engl J Med Date: 2017-02-16 Impact factor: 91.245
Authors: Samia Mora; Lisa R Yanek; Taryn F Moy; M Daniele Fallin; Lewis C Becker; Diane M Becker Journal: Circulation Date: 2005-04-19 Impact factor: 29.690
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Kurt Hoffmann; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Yijun Chen; Leonor Corsino; Prapimporn Chattranukulchai Shantavasinkul; John Grant; Dana Portenier; Laura Ding; Alfonso Torquati Journal: Ann Surg Date: 2016-06 Impact factor: 12.969
Authors: Y Nakamura; Y Horii; T Nishino; H Shiiki; Y Sakaguchi; T Kagoshima; K Dohi; Z Makita; H Vlassara; R Bucala Journal: Am J Pathol Date: 1993-12 Impact factor: 4.307
Authors: Jeroen Nijhuis; Francois M H van Dielen; Suomi M G Fouraschen; Maartje A J van den Broek; Sander S M Rensen; Wim A Buurman; Jan Willem M Greve Journal: Obesity (Silver Spring) Date: 2007-06 Impact factor: 5.002
Authors: Sayeed Ikramuddin; Judith Korner; Wei-Jei Lee; John P Bantle; Avis J Thomas; John E Connett; Daniel B Leslie; William B Inabnet; Qi Wang; Robert W Jeffery; Keong Chong; Lee-Ming Chuang; Michael D Jensen; Adrian Vella; Leaque Ahmed; Kumar Belani; Amy E Olofson; Heather A Bainbridge; Charles J Billington Journal: Diabetes Care Date: 2016-06-16 Impact factor: 19.112